AbbVie initiates Phase I trial of Covid-19 antibody
The antibody, ABBV-47D11, targets the virus spike protein’s conserved region. Credit: Viktor Forgacs on Unsplash.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
